We intend to become a leading biopharmaceutical company focused on neurological and psychiatric disorders, including orphan indications. Our business strategy
- Advancing SLS-002 in suicidality in PTSD and in major depressive disorder;
- Advancing SLS-006 in early stage and late stage Parkinson's disease as a monotherapy and adjunctive therapy, respectively;
- Filing an IND for SLS-008 in pediatric esophagitis and another undisclosed indication;
- Forming strategic collaborations in the European Union and Asian markets; and
- Acquiring synergistic assets in the central nervous system therapy space through licensing and partnerships.
Private Placement of Common Shares and Warrants
On September 20, 2018, we entered into the SPA with the Selling Stockholder for the sale by us in a private placement (the "Private Placement") of the
Shares and the Warrants. The Warrants are exercisable for five years from the initial exercise date. In addition, pursuant to the terms of the Purchase Agreement, outstanding warrants to
purchase up to 2,677,160 shares of Common Stock previously issued to and held by the Selling Stockholder were canceled at the closing of the Private Placement (the "Closing"). The Closing
occurred on September 24, 2018.
For a complete description of our business, financial condition, results of operations and other important information, we refer you to our filings with the SEC that are
incorporated by reference in this prospectus, including our Annual Report on Form 10-K for the year ended December 31, 2017. For instructions on how to find copies of these documents, see
"Where You Can Find More Information".
We were incorporated under the laws of the State of Nevada in 1987. On January 24, 2019, we completed a reverse merger transaction with Seelos Therapeutics, Inc.,
a Delaware corporation (now known as Seelos Corporation) ("STI") (the "Merger") and, upon completion of the Merger, we changed our name to Seelos Therapeutics,
Inc. On January 23, 2019, in connection with, and prior to the completion of, the Merger, the Company effected a reverse stock split of the Company's common stock, par value $0.001 per
share, at a ratio of 1-for-30 (the "Reverse Stock Split"). Shares of our common stock commenced trading on the Nasdaq Capital Market under the ticker symbol "SEEL"
as of market open on January 24, 2019. Unless otherwise noted, all references to share amounts, and other information in this prospectus have been adjusted to reflect the Reverse Stock
Split. Our principal executive offices are located at 300 Park Avenue, 12th Floor, New York, NY 10022, and our telephone number is (646) 998-6475. Our website is located at
www.seelostx.com. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way part of this prospectus and should not
be relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly and current reports, proxy statements and other
information with the SEC. You may obtain any of the documents filed by us with the SEC at no cost from the SEC's website at http://www.sec.gov.